Related Experiment Video

Updated: Aug 25, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer

P Brown1, D Small

  • 1Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA.

European Journal of Cancer (Oxford, England : 1990)
|March 11, 2004
PubMed

Insights

Molecularly-targeted cancer therapies, including FLT3 inhibitors, show promise for pediatric leukemias like acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Further research is needed to overcome challenges in their pediatric application.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Molecularly-targeted cancer therapeutics are a rapidly advancing field.
  • Clinical trials for pediatric cancer patients are increasingly incorporating these novel agents.

Purpose of the Study:

  • To review the current status of molecularly-targeted therapies for pediatric malignancies.
  • To focus on FLT3 receptor tyrosine kinase inhibitors for pediatric leukemias.

Main Methods:

  • Review of current literature on molecularly-targeted therapies in pediatric cancers.
  • Specific focus on FLT3 inhibitors and their role in pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Main Results:

  • FLT3 is a key target in pediatric leukemias, particularly AML and MLL-rearranged ALL.
  • Activating FLT3 mutations are associated with poor prognosis in pediatric AML.
  • FLT3 inhibitors show early promise in adult AML and have limited preclinical data in pediatric ALL.

Conclusions:

  • FLT3 inhibitors represent a promising targeted therapy for pediatric leukemias.
  • Challenges and future directions for targeted agents in pediatric oncology require further investigation.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...